News | July 06, 2024
Dabur India updates on Q1 FY25
Dabur's consolidated revenue is expected to register mid to high single digit growth during Q1 FY25
Dabur's consolidated revenue is expected to register mid to high single digit growth during Q1 FY25
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
Green Vision Centres cut emissions, expand community coverage as partners align on resilient eye health systems
Recognition across subsidiaries and geographies highlights pharma major’s focus on inclusive culture, employee experience, and global workforce development
Remidex manufactures micronutrient premixes and nutraceuticals,
The company’s consolidated revenues rose 17.5% year-on-year to Rs. 2,265 crore
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY
U.S. market achieved record quarterly sales of Rs. 3,113.2 crore ($350 million), a 54% YoY increase, accounting for 44% of global sales
The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year
Subscribe To Our Newsletter & Stay Updated
